201 related articles for article (PubMed ID: 11081570)
1. Capecitabine: preclinical pharmacology studies.
Ishitsuka H
Invest New Drugs; 2000 Nov; 18(4):343-54. PubMed ID: 11081570
[TBL] [Abstract][Full Text] [Related]
2. [Discovery and development of novel anticancer drug capecitabine].
Ishitsuka H; Shimma N; Horii I
Yakugaku Zasshi; 1999 Dec; 119(12):881-97. PubMed ID: 10630095
[TBL] [Abstract][Full Text] [Related]
3. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Endo M; Shinbori N; Fukase Y; Sawada N; Ishikawa T; Ishitsuka H; Tanaka Y
Int J Cancer; 1999 Sep; 83(1):127-34. PubMed ID: 10449619
[TBL] [Abstract][Full Text] [Related]
4. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine.
Shimma N; Umeda I; Arasaki M; Murasaki C; Masubuchi K; Kohchi Y; Miwa M; Ura M; Sawada N; Tahara H; Kuruma I; Horii I; Ishitsuka H
Bioorg Med Chem; 2000 Jul; 8(7):1697-706. PubMed ID: 10976516
[TBL] [Abstract][Full Text] [Related]
5. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Miwa M; Ura M; Nishida M; Sawada N; Ishikawa T; Mori K; Shimma N; Umeda I; Ishitsuka H
Eur J Cancer; 1998 Jul; 34(8):1274-81. PubMed ID: 9849491
[TBL] [Abstract][Full Text] [Related]
6. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.
Ishikawa T; Sekiguchi F; Fukase Y; Sawada N; Ishitsuka H
Cancer Res; 1998 Feb; 58(4):685-90. PubMed ID: 9485021
[TBL] [Abstract][Full Text] [Related]
7. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts.
Ishikawa T; Utoh M; Sawada N; Nishida M; Fukase Y; Sekiguchi F; Ishitsuka H
Biochem Pharmacol; 1998 Apr; 55(7):1091-7. PubMed ID: 9605432
[TBL] [Abstract][Full Text] [Related]
8. [Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
Saeki T; Takashima S
Gan To Kagaku Ryoho; 1999 Mar; 26(4):447-55. PubMed ID: 10097741
[TBL] [Abstract][Full Text] [Related]
9. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.
Sawada N; Ishikawa T; Fukase Y; Nishida M; Yoshikubo T; Ishitsuka H
Clin Cancer Res; 1998 Apr; 4(4):1013-9. PubMed ID: 9563897
[TBL] [Abstract][Full Text] [Related]
10. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts.
Sawada N; Ishikawa T; Sekiguchi F; Tanaka Y; Ishitsuka H
Clin Cancer Res; 1999 Oct; 5(10):2948-53. PubMed ID: 10537364
[TBL] [Abstract][Full Text] [Related]
11. Rational design of new tumoractivated cytotoxic agents.
Verweij J
Oncology; 1999 Jul; 57 Suppl 1():9-15. PubMed ID: 10436411
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine).
Ishikawa T; Fukase Y; Yamamoto T; Sekiguchi F; Ishitsuka H
Biol Pharm Bull; 1998 Jul; 21(7):713-7. PubMed ID: 9703255
[TBL] [Abstract][Full Text] [Related]
13. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
[TBL] [Abstract][Full Text] [Related]
14. Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Ninomiya I; Terada I; Yoshizumi T; Takino T; Nagai N; Morita A; Fushida S; Nishimura G; Fujimura T; Ohta T; Miwa K
Int J Cancer; 2004 Oct; 112(1):135-42. PubMed ID: 15305385
[TBL] [Abstract][Full Text] [Related]
15. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Mori K; Hasegawa M; Nishida M; Toma H; Fukuda M; Kubota T; Nagasue N; Yamana H; Hirakawa-YS Chung K; Ikeda T; Takasaki K; Oka M; Kameyama M; Toi M; Fujii H; Kitamura M; Murai M; Sasaki H; Ozono S; Makuuchi H; Shimada Y; Onishi Y; Aoyagi S; Mizutani K; Ogawa M; Nakao A; Kinoshita H; Tono T; Imamoto H; Nakashima Y; Manabe T
Int J Oncol; 2000 Jul; 17(1):33-8. PubMed ID: 10853015
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C.
Ogata Y; Matono K; Sasatomi T; Ishibashi N; Torigoe S; Fukumitsu T; Mizobe T; Yamashita N; Yanagawa T; Shirouzu K
J Surg Oncol; 2006 Jan; 93(1):47-55. PubMed ID: 16353181
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology and clinical status of capecitabine.
Schilsky RL
Oncology (Williston Park); 2000 Sep; 14(9):1297-306; discussion 1309-11. PubMed ID: 11033828
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine (Xeloda): from the laboratory to the patient's home.
Pentheroudakis G; Twelves C
Clin Colorectal Cancer; 2002 May; 2(1):16-23. PubMed ID: 12453332
[TBL] [Abstract][Full Text] [Related]
20. [Thymidine phosphorylase expressed in monocyte-macrophages enhanced anticancer effect of 5'-deoxy-5-fluorouridine on colorectal carcinoma cells].
Zhang JM; Liu MJ; Mizoi T; Shiiba K; Sasak I; Matsuno S
Zhonghua Yi Xue Za Zhi; 2004 May; 84(9):718-24. PubMed ID: 15200906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
